Prospective, Non-interventional, Multi-center Safety Study of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea

Bayer601 enrolled

Overview

The primary objective in this study is collecting post-marketing information on the safety. Thus, it includes information under the routine clinical practice on adverse events (AEs) and adverse drug reactions (ADRs) including expulsion and abnormal bleeding that occur within the first 12 months Mirena insertion. The secondary objective(s) in this study is/are collecting information on Mirena effectiveness, such as periodic blood loss and Quality of life (QOL), use of analgesic and dysmenorrhea pain as far as these are recorded under routine clinical practice.

This local, non-interventional, multicenter, single-cohort study using primary data includes patients treated with Mirena for Heavy menstrual bleeding(HMB) and/or dysmenorrhea (contraception is not included). A total of 600 patients (valid for safety analysis) is planned to be enrolled in two years. No formal sample size estimation was conducted, it was determined based on feasibility. Target population is patients with HMB and/or dysmenorrhea diagnosis. The treatment should be performed based on the product label in Japan. The standard observation period will last for 12 months from starting Mirena treatment.

Study Type

OBSERVATIONAL

Enrollment

601

Conditions

Menorrhagia, Dysmenorrhea

Interventions

Levonorgestrel IUS (Mirena, BAY86-5028)DRUG

The treatment of Mirena should comply with the local product information.

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Female patients diagnosed with HMB or/and dysmenorrhea. * Patients for whom newly starting treatment with Mirena was made as per investigator's routine treatment practice * Written informed consent Exclusion Criteria: * Patient whose purpose is only contraception

Locations (1)

Unnamed facility

Multiple Locations, Japan

Outcomes

Primary Outcomes

Number of participants with adverse drug reaction

Time frame: Up to 12 months

Number of participants with treatment-emergent adverse events (TEAEs)

Time frame: Up to 12 months

Secondary Outcomes

Change from baseline in bleeding characterized by Pictorial Blood loss Assessment Chart (PBAC) score to 12 months

Time frame: Baseline and 12 months

Change from baseline in monthly bleeding intensities (the number of spotting and/or bleeding days) to 12 months

Time frame: Baseline and 12 months

Change from baseline in Quality of Life parameters assessed using MMAS or MDQ score after 3 and 12 months

MMAS: Menorrhagia Multi Attribute Score for Heavy Menstrual Bleeding and MDQ: Menstrual Distress Questionnaire for dysmenorrhea

Time frame: Baseline and 3 months, Baseline and 12 months

Change from baseline in dysmenorrhea pain using Visual Analogue scale

Time frame: Baseline and 1 month, Baseline and 3 months, Baseline and 6 months, Baseline and 12 months

Change from baseline in use of analgesics after Mirena insertion

Time frame: Baseline and 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.